Muzastotug
Clinical Trials Overview
1 trials found
About Muzastotug
Muzastotug is an experimental compound being evaluated in early-phase clinical trials for microsatellite stable (MSS) colorectal cancer. Based on the available trial data, it is being tested in combination with established therapies including leucovorin, fluorouracil, and FOLFIRI regimens, suggesting it may serve as an adjunct to standard chemotherapy protocols. The drug appears to be specifically targeted toward MSS tumors, which typically have limited response to immunotherapy approaches.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
The specific molecular mechanism of action for Muzastotug has not been fully disclosed in publicly available trial information. Given its use in combination with chemotherapy regimens and focus on MSS colorectal cancers, it likely targets pathways involved in tumor growth or immune response modulation specific to microsatellite stable disease.
1
Total Trials
0
Recruiting
0
Active
0
Completed
30
Total Enrollment
1
Countries
NCT07363408
Phase 1
Not yet recruiting
30 patients
This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and leucovorin, fluorouracil, and i...
United States